Filing summary
Issuer and period: The supplied filing is Check-Cap Ltd.’s audited Form 20-F for the fiscal year ended December 31, 2016—not a filing for Mbody AI Ltd. or a standalone 2016 fourth quarter. The company reports under U.S. GAAP. Figures below are U.S. dollars unless stated otherwise.
Business context and reporting period
Check-Cap is a clinical-stage diagnostics company developing C-Scan, an ingestible, ultra-low-dose X-ray system intended to screen for colorectal polyps and cancer without cathartic bowel preparation. It had no product revenue and no marketing clearance in any jurisdiction at year-end. The financial statements were audited; the auditor expressed an unqualified opinion and noted the company’s dependence on future financing and commercialization to reach profitability.
Key financial metrics
| Metric | 2016 | 2015 |
|---|---|---|
| Revenue | None | None |
| R&D expense, net of grants | $5.49 million | $5.84 million |
| General and administrative expense | $3.57 million | $6.63 million |
| Operating loss | $9.06 million | $12.46 million |
| Net loss | $8.83 million | $12.29 million |
| Basic and diluted loss per share | $0.61 | $1.06 |
| Net cash used in operating activities | $7.92 million | $8.63 million |
| Cash and cash equivalents at year-end | $11.64 million | $9.39 million |
| Working capital | $10.51 million | $12.86 million |
| Total assets | $12.30 million | $15.30 million |
| Shareholders’ equity | $10.41 million | $12.65 million |
Gross margin and operating margin are not meaningful because the company had no revenue. Year-end current liabilities were $1.37 million; non-current royalty provisions were $0.52 million. No bank debt was outstanding at year-end; the $1 million Bank Leumi facility drawn in 2015 was repaid that year. Cash from financing activities was $5.42 million in 2016, primarily from the August registered direct offering; investing activities provided $4.69 million, mainly from maturing short-term deposits.
Changes versus prior period
- Net loss narrowed by $3.46 million, while operating loss fell by $3.40 million year over year.
- G&A declined $3.06 million, primarily because 2015 included larger one-time share-based compensation and other public-company, recruiting and professional-service costs.
- Net R&D expense decreased $0.35 million: higher NATI/BIRD grant participation and lower share-based compensation and contractor costs more than offset higher salaries and clinical-trial spending.
- Operating cash use decreased $0.71 million. Cash increased $2.25 million during 2016, supported by the registered direct offering and release of short-term deposits.
- Outstanding ordinary shares rose from 11.81 million to 15.21 million during 2016, including shares issued and warrants exercised; further dilution is a material consideration.
Outlook, commentary and risks
- Management expected increased R&D spending in 2017 and said available cash should fund planned operations through at least December 31, 2017. If financing were not obtained, management said downsizing could extend funding to at least June 30, 2018. These are management estimates, not assurance of funding sufficiency.
- The company expects significant additional financing to progress clinical trials and regulatory work; future equity financing may dilute shareholders. It reported a $42.9 million accumulated deficit and no history of profitability.
- Plans included a CE-mark submission in the first half of 2017, subject to clinical and quality-system milestones, and a possible European commercial launch in 2018, subject to results, approvals, capital and strategic partners. A U.S. pilot study was planned for 2017, a pivotal study for 2018, and a direct FDA de novo submission was anticipated in 2019. These plans are forward-looking.
- Preliminary results from the first 66 capsules in a feasibility study showed 65 naturally eliminated without reported major or minor side effects; average calculated radiation exposure was 0.06 mSv. Polyps were identified in several patients and later validated by colonoscopy. These limited, preliminary findings do not establish overall safety or diagnostic effectiveness.
- Key risks include clinical-trial failure or delay, regulatory uncertainty (including possible FDA PMA requirements), reimbursement and market adoption, manufacturing scale-up, reliance on single-source suppliers without written contracts, radioactive-material regulation, Israeli operating and grant restrictions, and the need for additional capital.
- NATI grants totaled $5.1 million received, with a contingent repayment obligation of $5.3 million at year-end; grant terms can constrain transfer of funded technology or manufacturing outside Israel. The filing also reports a $127,000 BIRD grant contingent obligation and an approximately $12,000 refund due.
- Management stated disclosure controls and internal control over financial reporting were effective at December 31, 2016; the auditor did not provide an internal-control attestation because the company was an emerging growth company. No material litigation or material off-balance-sheet arrangements were reported.
Investor verification priorities
- Confirm the issuer and filing identity: this document is Check-Cap Ltd.’s 2016 annual report, not Mbody AI Ltd.’s quarterly filing.
- Verify cash runway assumptions against subsequent cash use, financing and clinical-trial costs; assess whether the stated 2017 funding plan was achieved.
- Track trial enrollment, complete safety and polyp-detection results, and compare performance with colonoscopy before relying on preliminary findings.
- Confirm CE-mark and FDA pathway milestones, including whether regulators require additional studies or a PMA application.
- Assess dilution and potential share overhang from warrants, options and future fundraising, and review restrictions and repayment terms tied to NATI and BIRD support.